You can buy or sell MDGL and other stocks, options, and ETFs commission-free!
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA. The listed name for MDGL is Madrigal Pharmaceuticals, Inc. Common Stock.
Paul A. Friedman
West Conshohocken, Pennsylvania
52 Week High
52 Week Low
— per share
Expected Feb 24, Pre-Market